Altogether, our results herein demonstrate the synergistic effects of the PARP inhibitors and the arsenic compound in HR-proficient ovarian cancer cells in vitro and xenograft tumors derived from HR-proficient ovarian cancer cells in vivo, which do not respond well to the PARP inhibitors alone. The gene discussed is PARP1; the disease is ovarian carcinoma.